Cite
PCI29732, a Bruton's Tyrosine Kinase Inhibitor, Enhanced the Efficacy of Conventional Chemotherapeutic Agents in ABCG2-Overexpressing Cancer Cells.
MLA
Chunlei Ge, et al. “PCI29732, a Bruton’s Tyrosine Kinase Inhibitor, Enhanced the Efficacy of Conventional Chemotherapeutic Agents in ABCG2-Overexpressing Cancer Cells.” Cellular Physiology & Biochemistry (Karger AG), vol. 48, no. 6, Aug. 2018, pp. 2302–17. EBSCOhost, https://doi.org/10.1159/000492647.
APA
Chunlei Ge, Fang Wang, Chaochu Cui, Xiaodong Su, Kenneth Kin Wah To, Xiaokun Wang, Hui Zhang, Xin Song, & Liwu Fu. (2018). PCI29732, a Bruton’s Tyrosine Kinase Inhibitor, Enhanced the Efficacy of Conventional Chemotherapeutic Agents in ABCG2-Overexpressing Cancer Cells. Cellular Physiology & Biochemistry (Karger AG), 48(6), 2302–2317. https://doi.org/10.1159/000492647
Chicago
Chunlei Ge, Fang Wang, Chaochu Cui, Xiaodong Su, Kenneth Kin Wah To, Xiaokun Wang, Hui Zhang, Xin Song, and Liwu Fu. 2018. “PCI29732, a Bruton’s Tyrosine Kinase Inhibitor, Enhanced the Efficacy of Conventional Chemotherapeutic Agents in ABCG2-Overexpressing Cancer Cells.” Cellular Physiology & Biochemistry (Karger AG) 48 (6): 2302–17. doi:10.1159/000492647.